{"id":799234,"date":"2025-01-09T08:07:34","date_gmt":"2025-01-09T13:07:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/"},"modified":"2025-01-09T08:07:34","modified_gmt":"2025-01-09T13:07:34","slug":"esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/","title":{"rendered":"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET."},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2013 Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease \u2013<\/em>\n      <\/p>\n<p align=\"left\">ANN ARBOR, Mich., Jan.  09, 2025  (GLOBE NEWSWIRE) &#8212; Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL<sup>\u00ae<\/sup> (bempedoic acid) and NEXLIZET<sup>\u00ae<\/sup> (bempedoic acid and ezetimibe).<\/p>\n<p>The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Patrick Moriarty, M.D.<\/strong>, Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis &amp; Lipid-Apheresis Center.<\/li>\n<\/ul>\n<p>Registration for the KOL webinar can be found <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GFe8t5HC86Ly4WjJTsYvx75zWfNlpIwCwogGt_lT_kueZqsrw3vU2Dsd7UbgIHSUIP2n3imE6d4mA0iapaT6g7kuDY4t3Xexp8vyVnFv-zM=\" rel=\"nofollow\" target=\"_blank\">here<\/a>. A live audio webcast can be accessed on the investor and media section of the Esperion <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qx81fYvja8MhWP_IRAvQO0YRa-aBs5NzSwkaqNMG_3jYJUqL8DKKFlrJIbkbJMJ7GeyILWF2Dkw62s-SpdEmeWOqf4pT2sorG1BACULmUmiqYestit74PvuYXeNNJJZ4xBv7PEClUrdkqXp12HPVHsW2TLkeuJWmkcNy83jx3qhOnrElxA6UpEnZ3igjZQEz9F1T3dFcJPwF9UqnlOxMyOUslwDXsUkm3XACKKAvZZu4XWoBr4OyY1F6M0CT61idmGWIi6EdOdOrsPpaEf0Ewg==\" rel=\"nofollow\" target=\"_blank\">website<\/a>. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company&#8217;s website for approximately 90 days.<\/p>\n<p>\n        <strong>Esperion Therapeutics<\/strong><br \/>\n        <br \/>Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.<\/p>\n<p>Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-IDYc49487suvOBIjXQHVzikZFBCOLrHvv8fdz23aL4SnfuhCg4-ZCFwEeP7GT4FwwOLDk5ISOG17vbSwPqEVQ==\" rel=\"nofollow\" target=\"_blank\">esperion.com<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-IDYc49487suvOBIjXQHVz7By9eS24SeCqdxtYS-h0LgSzLSFOCePffVzsl0N4dQ-gDQU5Mt5XE4zrJXrhodI-euf0rge0Y8XOEFpohZUnk=\" rel=\"nofollow\" target=\"_blank\">esperionscience.com<\/a> and follow Esperion on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZKn3C1bndpYsVY71Xcf3uzWuQ8nh2BklCc9gpCHw_QEp5Ip9i6tZal3R731L9A0vP4EIfeSmxAIjAIrnZcmIJmUng7Irja3JPm_dJUiF0TfIqWD7-rDCwfulvrD4F4Ht\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wVhgDYzoJl6G2ef0qo4nGJNWXwuzjrJS1uLoaNgCQ9jix1XMTM_JtzpRvmMULdtwPxHTNm_pe332N6CmMphp7g==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Esperion Contact Information:<\/strong>\u00a0<br \/>Investors:\u00a0\u00a0<br \/>Alina Venezia\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XW8FPKL27Je2CWpCEF-ZI1V6hGoDmgrNOlGdZ12ifLWgQuFxgaoOFNntlz3HF9V8bIZ3yvk_uUuzql3WzYJWCDFSzMQWFPBXtk4ltNnc3ZMosSbdgFfYJ3D9P3p7AxOC\" rel=\"nofollow\" target=\"_blank\">investorrelations@esperion.com<\/a>\u00a0\u00a0<br \/>(734) 887-3903\u00a0<\/p>\n<p>Media:\u00a0\u00a0<br \/>Tiffany Aldrich\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EXuwkgIgTagZal4-asO6uoF2XOPXR0y5hPEG9NF_MvUcLTZFNNfVB-P377m31g2thbjQ-pRRUvhVZMrupb5y4xKf6kVJPogvTlmpZtbv7P-07AyWlyb8KhjqYntwSrA4\" rel=\"nofollow\" target=\"_blank\">corporateteam@esperion.com<\/a><br \/>(616) 443-8438\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDZhZWM2ZWEtMTBiOS00ODliLWE5NDQtYTM5M2UwYWY1ZDdmLTEwMTg3MTQ=\/tiny\/Esperion-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease \u2013 ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) &#8212; Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL\u00ae (bempedoic acid) and NEXLIZET\u00ae (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis &amp; Lipid-Apheresis Center. Registration for the KOL webinar can be found here. A live audio webcast can be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799234","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease \u2013 ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) &#8212; Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL\u00ae (bempedoic acid) and NEXLIZET\u00ae (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis &amp; Lipid-Apheresis Center. Registration for the KOL webinar can be found here. A live audio webcast can be &hellip; Continue reading &quot;Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T13:07:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.\",\"datePublished\":\"2025-01-09T13:07:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/\",\"name\":\"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=\",\"datePublished\":\"2025-01-09T13:07:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/","og_locale":"en_US","og_type":"article","og_title":"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Market Newsdesk","og_description":"\u2013 Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease \u2013 ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) &#8212; Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL\u00ae (bempedoic acid) and NEXLIZET\u00ae (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis &amp; Lipid-Apheresis Center. Registration for the KOL webinar can be found here. A live audio webcast can be &hellip; Continue reading \"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-09T13:07:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.","datePublished":"2025-01-09T13:07:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/"},"wordCount":353,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/","name":"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=","datePublished":"2025-01-09T13:07:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTA4MyM2Njg1ODU4IzIwMDcxNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-to-host-virtual-key-opinion-leader-event-on-wednesday-january-22-2025-at-1130-a-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799234"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799234\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}